RecruitingPhase 2NCT07172919

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study

Sponsor

Amgen

Enrollment

14 participants

Start Date

Jan 2, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Panitumumab and a drug called Sotorasib for people with advanced solid tumors. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSotorasib

Sotorasib will be administered orally as a tablet.

DRUGPanitumumab

Panitumumab will be administered as an IV infusion.

Locations(11)

Florida Cancer Specialists - Fort Myers

Fort Myers, Florida, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Scientia Clinical Research Ltd

Randwick, New South Wales, Australia

Centre Leon Berard

Lyon, France

Evangelische Lungenklinik

Berlin, Germany

Henry Dunant Hospital Center

Athens, Greece

Theagenion Cancer Hospital

Thessaloniki, Greece

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, Japan

Universitaetsspital Basel

Basel, Switzerland

Taichung Veterans General Hospital

Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07172919

Related Trials

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT0583632439 locations